Trial Profile
Randomised, double-masked, controlled trial of intravitreal Avastin (bevacizumab) versus Triesence (triamcinolone) at the time of cataract surgery on the visual outcomes for patients with diabetic macular oedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Triamcinolone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms DIMECAT
- 15 Sep 2021 (3597231) Full text isn't accessible
- 08 Jun 2016 Status changed from recruiting to completed.
- 08 Jun 2016 Planned number of patients changed from 50 to 100.